Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition
SEATTLE--(BUSINESS WIRE)--Nov 29, 2018--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory program, ALPN-101, will be included in an oral presentation at the 60 th American Society of Hematology (ASH) Annual Meeting and Exposition on Sunday, December 2, 2018 at 9:30am PT in San Diego, CA.
The presentation highlights the novel role ICOS ligand (ICOS-L) plays in acute GvHD, extending what is currently understood about the CD28/B7 protein family in disease pathogenesis. In particular, there is a strong correlation with ICOS-L positive plasmacytoid dendritic cells and the gastrointestinal manifestations of GvHD that may act as a biomarker for identification of patients. There are no current therapies in development blocking both the CD28 and ICOS pathways. The oral presentation will include data evaluating ALPN-101, a highly potent and effective first in class dual blocker of both the ICOS and CD28 pathways, in GvHD and discuss its potential role and mechanism. It will be delivered by Dr. Djamilatou Adom from the Indiana University School of Medicine laboratory of Dr. Sophie Paczesny.
“I’m excited about the potential of ALPN-101 in GvHD given its dual CD28/ICOS mechanism of action,” said Dr. Paczesny, Professor of Immunology and Pediatrics at Indiana University School of Medicine and lead of the Biomarkers Stem Cell Transplantation Program, and one of Alpine’s research collaborators. “Targeting the ICOS/ICOSL and CD28/B7 pathways may represent a new avenue to treat or prevent GvHD, and early biomarker development could identify patients at risk and support ALPN-101 as an early intervention in this patient population.”
Oral PresentationTitle: ICOSL+ Plasmacytoid Dendritic Cells As Biomarker and Inducer of Graft-Versus-Host Disease Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Biomarkers and the Microbiome Date and Time: Sunday, December 2, 2018 at 9:30-9:45 a.m. PT Location: Grand Hall A of the Manchester Grand Hyatt San Diego.
As previously announced, the company will also have two poster presentations at the ASH Annual Meeting. Both posters will be available in Hall GH of the San Diego Convention Center on Saturday, December 1, 2018 from 6:15 p.m. PT – 8:15 p.m. PT:
Poster PresentationsAbstract Title: Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH) Session Name: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I Publication Number: 2037 Abstract Title: “Switch” Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells Session Name: 703. Adoptive Immunotherapy: Poster I Publication Number: 2052
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients’ lives. Supported by promising preclinical data, we aim to have two programs in the clinic in 2019. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 T cell costimulator intended to combine checkpoint inhibition with a necessary costimulation signal – an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181129005139/en/
CONTACT: Investor Relations:
Courtney Dugan, 212-257-6723
Jennifer Paganelli, 347-658-8290
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA WASHINGTON
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Alpine Immune Sciences, Inc.
Copyright Business Wire 2018.
PUB: 11/29/2018 07:00 AM/DISC: 11/29/2018 07:01 AM